Future work employing CRISPR-mediated allele editing in immune andneuronal cell types, coupled with palmitoylation and antigen-presentation assays,will be critical to validate the causal contribution of ZDHHC2 and SCRN1 toBD–IBD pathophysiology. This evidence concerns the gene SCRN1 and inflammatory bowel disease.